A lab-tested CJC-1295 and Ipamorelin blend refers to high-purity, synthetically manufactured growth hormone secretagogues verified via RP-HPLC, ESI-MS, and endotoxin testing for analytical rigor. CJC-1295 acts as a long-acting growth-hormone-releasing hormone (GHRH) analog that sustains GH and downstream IGF-1 levels, while Ipamorelin selectively targets the ghrelin receptor to stimulate pulsatile GH release without elevating cortisol or prolactin.
A lab-tested CJC-1295 and Ipamorelin blend refers to high-purity, synthetically manufactured growth hormone secretagogues verified via RP-HPLC, ESI-MS, and endotoxin testing for analytical rigor. CJC-1295 acts as a long-acting growth-hormone-releasing hormone (GHRH) analog that sustains GH and downstream IGF-1 levels, while Ipamorelin selectively targets the ghrelin receptor to stimulate pulsatile GH release without elevating cortisol or prolactin.
In biomedical research, the combination of CJC-1295 (without Drug Affinity Complex, or No DAC) and Ipamorelin represents one of the most widely evaluated dual-secretagogue models. CJC-1295 is a 29-amino acid tetrasubstituted peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). By modifying positions 2, 8, 15, and 27 of the native sequence, researchers created a peptide resistant to rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). Studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, CJC-1295 extends the plasma half-life relative to native GHRH(1-29).
Ipamorelin, conversely, is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue receptor (GHSR-1a) agonist. When combined in analytical settings using our CJC-1295 Ipamorelin blend, these two compounds operate on complementary biochemical pathways. Ensuring that these peptides are thoroughly lab-tested before introduction to cell cultures or animal models is critical to eliminating uncharacterized artifacts caused by sequence truncations, counterion residues, or microbial endotoxins.
The primary objective of co-evaluating CJC-1295 and Ipamorelin in laboratory settings is to observe their synergistic impact on somatotroph signaling within the anterior pituitary. Native GH secretion relies on coordinated signaling between GHRH receptors and ghrelin/growth hormone secretagogue receptors. CJC-1295 binds to the GHRH receptor, triggering Gs protein activation, adenylate cyclase stimulation, intracellular cyclic AMP (cAMP) elevation, and protein kinase A (PKA) phosphorylation. This cascade promotes both growth hormone gene transcription and initial vesicle mobilization.
Ipamorelin binds independently to the Gq protein-coupled GHSR-1a receptor, activating phospholipase C (PLC) and leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). This pathway triggers intracellular calcium ion release from the endoplasmic reticulum, prompting exocytosis of pre-stored GH vesicles. Preclinical models indicate that simultaneous activation of both the cAMP/PKA and IP3/DAG pathways yields a greater amplitude of endogenous growth hormone discharge than isolated GHRH or GHRP receptor activation alone. Researchers interested in exploring these biochemical cascades can reference our broader growth hormone secretagogue research hub.
In animal models, administration of CJC-1295 without DAC combined with Ipamorelin demonstrates marked elevations in circulating growth hormone and insulin-like growth factor 1 (IGF-1). Unlike classical GHRPs such as GHRP-2 or GHRP-6, Ipamorelin exhibits high receptor selectivity. In vitro pituitary cell cultures and rodent assays show that Ipamorelin does not induce significant secretagogue activity for adrenocorticotropic hormone (ACTH), cortisol, or prolactin, even at concentrations far exceeding the EC50 for GH release. This selectivity allows researchers to study isolated GH/IGF-1 axis signaling without confounding systemic stress hormone spikes.
Downstream IGF-1 signaling plays a critical role in preclinical models of extracellular matrix remodeling, satellite cell proliferation, myoblast differentiation, and osteoblast collagen synthesis. Investigating these pathways requires precise control over compound purity, as impurities can alter ligand-binding kinetics or induce non-specific receptor internalization. Comparative studies, such as evaluations of CJC-1295 vs Sermorelin, highlight how structural modifications in CJC-1295 prolong receptor occupancy compared to shorter-lived native analogs.
To guarantee valid, reproducible experimental data, every lot of CJC-1295 Ipamorelin must undergo rigorous analytical verification by independent laboratories. The gold standard for peptide purity assessment is Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). RP-HPLC separates the target peptide sequence from synthesis side-products, deletion sequences, and residual protecting groups based on hydrophobic interaction with a stationary phase column. A high purity rating (typically ≥99.0%) indicates that non-target peptide fragments are minimized below detection thresholds.
Complementing HPLC, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms molecular identity. ESI-MS measures the mass-to-charge ratio (m/z) of ionized molecules, providing exact molecular weight verification for both CJC-1295 (C152H252N44O42, theoretical MW: 3367.9 g/mol) and Ipamorelin (C38H49N9O5, theoretical MW: 711.86 g/mol). A comprehensive Certificate of Analysis (COA) integrates both RP-HPLC chromatograms and MS spectra, confirming that the physical contents of the vial match the expected chemical structure without unexpected degradation adducts.
Bacterial endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—present a major risk in preclinical peptide research. In vitro, endotoxins introduce non-specific cytokine release (such as TNF-alpha and IL-6) in cell cultures, skewing cellular survival and gene expression assays. In animal models, elevated endotoxin levels can trigger febrile responses, systemic inflammatory cascades, or septic shock, invalidating metabolic and physiological research outcomes.
PX1 Research enforces strict endotoxin screening protocols using Chromogenic Reagent Limulus Amebocyte Lysate (LAL) assays. Laboratory-tested batches must meet stringent threshold limits (typically <0.5 EU/mg), ensuring compatibility with sensitive biological assays. Institutional buyers managing large-scale preclinical trials can explore our wholesale research accounts to obtain bulk lot quantities backed by full analytical transparency and standardized endotoxin documentation.
When designing preclinical protocols to evaluate the GH/IGF-1 axis, investigators must select secretagogues that match specific half-life requirements and receptor selectivity profiles. Below is a comparative overview of common research secretagogues evaluated alongside the CJC-1295/Ipamorelin combination:
CJC-1295 No DAC provides an extended half-life (approximately 30 minutes in rodents) compared to native GHRH analogs like Sermorelin (half-life <10 minutes), while avoiding the multi-day continuous elevation associated with CJC-1295 DAC. Meanwhile, Ipamorelin offers superior target selectivity over earlier hexapeptides like GHRP-6, which can induce undesirable spikes in plasma cortisol and prolactin. Combining CJC-1295 No DAC with Ipamorelin recreates a physiological, pulsatile growth hormone surge while extending overall secretagogue window duration in laboratory models.
Lyophilized CJC-1295 and Ipamorelin peptides are provided as stable, freeze-dried cakes designed to preserve peptide bond stability during transport. Upon receipt, lyophilized vials should be stored in a controlled freezer environment at -20°C or -80°C to prevent moisture uptake and hydrolytic degradation. Prior to reconstituting, vials should be allowed to equilibrate to room temperature inside a laminar flow hood to avoid condensation on the inner glass surface.
For reconstitution in aseptic research environments, sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution should be introduced gently along the internal glass wall of the vial. Direct stream deposition onto the lyophilized cake should be avoided to prevent mechanical shearing of the peptide matrix. Gentle swirling is recommended until full solubilization is achieved; vigorous agitation or vortexing must be avoided. Once reconstituted, solution aliquots should be maintained at 2°C to 8°C for short-term evaluation or flash-frozen at -80°C to minimize degradation over repeated freeze-thaw cycles.
Achieving reproducible research outcomes requires sourcing materials from domestic manufacturers adhering to strict quality control standards. PX1 Research manufactures peptides in USA-based, GMP-compliant facilities utilizing automated solid-phase peptide synthesis (SPPS). Every synthesis batch undergoes ISO 17025 accredited third-party testing to verify chemical identity, purity, peptide content, and endotoxin levels prior to release.
Our catalog of lab-tested research peptides provides institutional laboratories, academic researchers, and private facilities with fully traceable, research-grade compounds. Orders are dispatched directly from our California and Arizona distribution hubs with same-day shipping on business days, preserving compound integrity and minimizing supply chain disruptions.
What analytical tests verify that CJC-1295 Ipamorelin is lab tested?
A fully verified batch is analyzed using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity percentage, Electrospray Ionization Mass Spectrometry (ESI-MS) for mass verification, and Limulus Amebocyte Lysate (LAL) testing for bacterial endotoxin quantification. Every batch from PX1 Research includes a lot-specific Certificate of Analysis (COA).
What is the primary difference between CJC-1295 No DAC and CJC-1295 DAC?
CJC-1295 No DAC (also known as Modified GRF 1-29) lacks the Drug Affinity Complex side-chain, giving it a half-life of approximately 30 minutes that induces physiological GH pulses. CJC-1295 DAC covalently binds to endogenous albumin, extending its biological half-life to several days and producing continuous elevation of baseline GH levels.
Why are CJC-1295 and Ipamorelin evaluated together in research?
CJC-1295 activates the GHRH receptor pathway (cAMP/PKA), while Ipamorelin selectively activates the ghrelin/GHSR-1a pathway (IP3/DAG/Ca2+). In preclinical models, simultaneous stimulation of both distinct signaling cascades produces a synergistic increase in pituitary growth hormone secretion.
What is the typical endotoxin limit for laboratory-grade peptides?
For cell culture and animal model applications, endotoxin levels should ideally measure below 0.5 EU/mg. Higher endotoxin levels can induce non-specific inflammatory signaling, confounding cellular and physiological research data.
How should reconstituted CJC-1295 Ipamorelin solutions be stored in the lab?
Reconstituted liquid solutions should be stored at 2°C to 8°C for short-term work (up to several weeks depending on buffer choice) or aliquoted and stored at -80°C for long-term storage. Repeated freeze-thaw cycles must be avoided to prevent peptide degradation.
Does Ipamorelin stimulate cortisol or prolactin release in preclinical models?
No. In vitro and animal studies consistently demonstrate that Ipamorelin is highly selective for the GHSR-1a receptor and does not trigger measurable release of ACTH, cortisol, or prolactin, setting it apart from non-selective secretagogues like GHRP-2 or GHRP-6.
What solvent is recommended for reconstituting lyophilized secretagogue blends?
Bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride (saline) are standard diluents used in laboratory settings to reconstitute lyophilized peptide cakes while inhibiting microbial growth.
Where are PX1 Research peptides synthesized and shipped from?
PX1 Research peptides are manufactured in USA-based, GMP-compliant facilities and undergo independent ISO 17025 lab testing. Orders ship directly from our fulfillment hubs in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.